Esperion Therapeutics, Inc.
ESPR
$3.78
$0.123.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.83M | -104.02M | -153.22M | -51.75M | -86.77M |
| Total Depreciation and Amortization | 106.00K | 106.00K | 89.00K | 63.00K | 42.00K |
| Total Amortization of Deferred Charges | 2.54M | 2.14M | 1.76M | 1.50M | 1.76M |
| Total Other Non-Cash Items | 24.52M | 25.46M | 77.96M | 87.06M | 94.48M |
| Change in Net Operating Assets | -14.63M | -48.01M | -26.70M | -60.53M | -35.27M |
| Cash from Operations | -93.29M | -124.33M | -100.11M | -23.65M | -25.76M |
| Capital Expenditure | 0.00 | -167.00K | -244.00K | -317.00K | -317.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | 0.00 | -167.00K | -244.00K | -317.00K | -317.00K |
| Total Debt Issued | 99.73M | 99.73M | 99.73M | 99.73M | -- |
| Total Debt Repaid | -210.09M | -210.09M | -210.09M | -210.09M | -- |
| Issuance of Common Stock | 13.52M | 3.38M | 9.60M | 106.04M | 115.09M |
| Repurchase of Common Stock | -47.00K | -47.00K | -343.80M | -343.80M | -343.75M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 137.91M | 128.28M | 432.94M | 434.60M | 284.62M |
| Cash from Financing | 41.02M | 21.25M | -11.62M | 86.48M | 55.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.27M | -103.24M | -111.98M | 62.51M | 29.88M |